Rationale, design, and baseline characteristics of the Cardiovascular Prognostic COUPLING Study in Japan (the COUPLING Registry).


Journal

Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554

Informations de publication

Date de publication:
03 2020
Historique:
received: 24 10 2019
accepted: 31 10 2019
pubmed: 25 2 2020
medline: 27 5 2021
entrez: 25 2 2020
Statut: ppublish

Résumé

Vascular biomarkers, including the cardio-ankle vascular index (CAVI), are increasingly being recognized as important indicators of cardiovascular risk. CAVI has been shown to have good discriminative ability for detecting new-onset hypertension, but results of studies investigating cardiovascular risk prediction are inconsistent. Furthermore, there is a lack of data on the prognostic value of changes in CAVI over time. The Cardiovascular Prognostic Coupling study was designed to determine the impact of baseline CAVI and changes in CAVI on cardiovascular events in a Japanese cohort. The design of the ongoing, multicenter, prospective, observational registry and baseline characteristics of the enrolled population are reported. Eligible consecutive patients were aged ≥30 years, had ≥1 cardiovascular risk factor, and were being treated according to relevant Japanese guidelines. The primary outcome is time to onset of a major cardiovascular event (a composite of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, stroke of unknown etiology, myocardial infarction, cardiovascular intervention for angina pectoris, and sudden death). Screening and enrollment occurred over a period of 3 years, followed by ≥7 years of follow-up, with CAVI determined annually. A total of 5279 patients were registered, of whom 5109 had baseline data available and will be included in future analyses. Mean CAVI at baseline was 8.8 ± 1.4. The proportion of patients with CAVI of <8, 8-10 or >10 was 25.3%, 57.0%, and 17.7%, respectively. Data from this registry should provide information on the significance of baseline CAVI and change in CAVI as indicators of cardiovascular prognosis in a representative patient population.

Identifiants

pubmed: 32092246
doi: 10.1111/jch.13764
pmc: PMC8029964
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

465-474

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

J Atheroscler Thromb. 2019 May 1;26(5):465-475
pubmed: 30518727
J Atheroscler Thromb. 2011;18(11):924-38
pubmed: 21628839
Hypertens Res. 2014 Nov;37(11):1014-20
pubmed: 25007768
Medicina (Kaunas). 2015;51(3):152-158
pubmed: 28705477
J Clin Hypertens (Greenwich). 2019 Jan;21(1):16-24
pubmed: 30456903
Atherosclerosis. 2014 Jul;235(1):239-45
pubmed: 24861728
J Clin Hypertens (Greenwich). 2020 Mar;22(3):465-474
pubmed: 32092246
J Am Coll Cardiol. 2011 May 3;57(18):1838-45
pubmed: 21527159
J Atheroscler Thromb. 2015;22(12):1255-65
pubmed: 26269147
Hypertens Res. 2003 Aug;26(8):615-22
pubmed: 14567500
J Atheroscler Thromb. 2016 May 2;23(5):596-605
pubmed: 26632164
Am J Hypertens. 2014 Jul;27(7):939-47
pubmed: 24473255
Clin Exp Hypertens. 2019;41(8):774-778
pubmed: 30632806
J Hypertens. 2015 Sep;33(9):1742-57; discussion 1757
pubmed: 26114836
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Am J Hypertens. 2015 Jan;28(1):7-9
pubmed: 25315475
Pulse (Basel). 2015 Sep;3(2):118-33
pubmed: 26587461
Atherosclerosis. 2015 Oct;242(2):461-8
pubmed: 26295798
J Clin Hypertens (Greenwich). 2018 Jun;20(6):1073-1077
pubmed: 29806107
Circ Res. 2019 Mar 29;124(7):990-1008
pubmed: 30920932
Circ J. 2016;80(4):1034-40
pubmed: 26936237
Circ J. 2016 May 25;80(6):1420-6
pubmed: 27116899
Pulse (Basel). 2019 Apr;6(3-4):131-136
pubmed: 31049312
Hypertension. 2007 Dec;50(6):991-7
pubmed: 17954719
Hypertension. 2019 Jan;73(1):75-83
pubmed: 30571549
Circulation. 2008 Dec 16;118(25):2702-9
pubmed: 19106393
Ther Apher Dial. 2012 Jun;16(3):232-41
pubmed: 22607566
Circulation. 1999 Sep 28;100(13):1481-92
pubmed: 10500053
J Vasc Surg. 2007 Jan;45 Suppl S:S5-67
pubmed: 17223489
Heart. 2006 Dec;92(12):1752-9
pubmed: 16621883
Nat Rev Nephrol. 2013 Dec;9(12):726-38
pubmed: 24189649
Hypertension. 2017 Jun;69(6):1045-1052
pubmed: 28438905
Int J Med Sci. 2019 Jun 7;16(7):939-948
pubmed: 31341407

Auteurs

Kazuomi Kario (K)

Jichi Medical University School of Medicine, Shimotsuke, Japan.

Tomoyuki Kabutoya (T)

Jichi Medical University School of Medicine, Shimotsuke, Japan.

Takeshi Fujiwara (T)

Jichi Medical University School of Medicine, Shimotsuke, Japan.

Keita Negishi (K)

Jichi Medical University School of Medicine, Shimotsuke, Japan.

Masafumi Nishizawa (M)

Minamisanriku Hospital, Motoyoshigun, Japan.

Mitsuyoshi Yamamoto (M)

Kotake Municipal Hospital, Kurate, Japan.

Kayo Yamagiwa (K)

Yamagiwa Clinic, Kasugai, Japan.

Akihiro Kawashima (A)

Kawashima Cardiology Clinic, Yaita, Japan.

Tetsuro Yoshida (T)

Onga Nakama Medical Association Onga Hospital, Onga, Japan.

Jun Nakazato (J)

Okinawa Chubu Hospital, Uruma, Japan.

Yoshio Matsui (Y)

Matsui Medical Clinic, Iwakuni, Japan.

Hiromitsu Sekizuka (H)

Fujitsu Clinic, Kawasaki, Japan.

Hideyasu Abe (H)

Abe Internal Medicine Clinic, Kobe, Japan.

Yasuhisa Abe (Y)

Abe Internal Medicine Clinic, Kobe, Japan.

Yumiko Fujita (Y)

Fujita Neurosurgical Clinic, Mitoyo, Japan.

Kei Sato (K)

Critical Care Research Group, The Prince Charles Hospital, Brisbane, Qld, Australia.

Keisuke Narita (K)

Karatsu City Madarashima Clinic, Karatsu, Japan.

Norihiro Tsuchiya (N)

Omotesando-naika-ganka Clinic, Minatoku, Tokyo, Japan.

Yoshiaki Kubota (Y)

Kubota Clinic, Toshimaku, Tokyo, Japan.

Toshikazu Hashizume (T)

National Hospital Organization Minami Wakayama Medical Center, Tanabe, Japan.

Satoshi Hoshide (S)

Jichi Medical University School of Medicine, Shimotsuke, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH